# 2026-13374: HHS Finally Ends Long-Running COVID Emergency Drug Rules

2026-13374, Termination of Declaration Authorizing Emergency Use of Drug and Biological Products During the COVID-19 Pandemic, is a Federal Register notice from Health and Human Services Department published 2026-07-02, effective 2027-06-29; PRIA reads it as touching household money (as of 2026-07-09).

- Canonical: https://policyrisk.com/federal-register/2026-13374
- As of: 2026-07-09
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-13374
- Title: Termination of Declaration Authorizing Emergency Use of Drug and Biological Products During the COVID-19 Pandemic
- Type: Notice
- Agencies: Health and Human Services Department
- Citation: 91 FR 40546
- Published: 2026-07-02
- Effective: 2027-06-29
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-09

## In one line

HHS Finally Ends Long-Running COVID Emergency Drug Rules

## Summary

The U.S. Department of Health and Human Services is ending the special emergency rules that allowed quick use of COVID-19 drugs and vaccines. This change affects companies, healthcare workers, and patients who relied on these emergency approvals. The emergency use authorization will officially stop on June 29, 2027, giving everyone time to adjust without sudden disruptions or extra costs.

## Abstract

The Secretary of Health and Human Services is issuing this notice pursuant to section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C) Act. On February 4, 2020, as amended on March 15, 2023, the HHS Secretary determined that there is a public health emergency, or significant potential for a public health emergency, that affects, or has a significant potential to affect, national security or the health and security of United States (U.S.) citizens living abroad, and that involves the virus (later referred to as SARS-CoV-2) that causes COVID- 19. Based on this determination, on March 27, 2020, the HHS Secretary declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic. On June 29, 2026, the HHS Secretary determined that circumstances no longer exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic. Based on this determination, the HHS Secretary is terminating this declaration, effective on June 29, 2027.

## Effects PRIA read

- EUA Declaration Ends June 29, 2027: cost, medium. The special HHS declaration that allowed Emergency Use Authorizations (EUAs) for COVID-19 drugs and biological products will terminate effective June 29, 2027. This ends the legal basis for issuing new EUAs under that declaration and affects companies, healthcare workers, and patients who relied on…
- 12-Month Transition: No New EUA Reviews: cost, medium. HHS is providing 12 months' advance notice and FDA has decided it will decline to review or process any new EUA requests for COVID-19 drugs or biological products during that 12-month transition period. FDA will only review EUA amendments during that period if they are necessary to protect public h…
- Path to Full Approval and Access Options: benefit, medium. FDA is encouraging sponsors of EUA products to seek full approval by submitting New Drug Applications (NDAs) or Biologics License Applications (BLAs), and says the 12-month transition period is a reasonable time for sponsors to generate data to support such submissions. If a gap exists between the…
- Some COVID-19 EUAs Revoked; Products Licensed: benefit, low. The notice states that EUAs for COVID-19 vaccines and convalescent plasma have already been revoked and that there are now COVID-19 vaccines and convalescent plasma products licensed through traditional Biologics License Applications (BLAs). The FDA also says there are FDA-approved therapeutic opti…

## Related documents

- [2026-22812](https://policyrisk.com/federal-register/2026-22812): Medicare and Medicaid Programs; Cutting Administrative Requirements for Excellence in Patient Care, 2026-11-10
- [2026-22792](https://policyrisk.com/federal-register/2026-22792): Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program, 2026-11-09
- [2026-22750](https://policyrisk.com/federal-register/2026-22750): Calendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the E…, 2026-11-09
- [2026-22743](https://policyrisk.com/federal-register/2026-22743): Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage…, 2026-11-09
- [2026-22739](https://policyrisk.com/federal-register/2026-22739): Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; i…, 2026-11-06
- [2026-22381](https://policyrisk.com/federal-register/2026-22381): Medicare and Medicaid Programs; Organ Procurement Organizations Conditions for Coverage: Revisions to the Conditions for Coverage, 2026-11-03

## Sources
- [2026-13374 on federalregister.gov](https://www.federalregister.gov/documents/2026/07/02/2026-13374/termination-of-declaration-authorizing-emergency-use-of-drug-and-biological-products-during-the)
- [2026-13374 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-07-02/pdf/2026-13374.pdf)

## Related
- [Previous: 2026-13373, Termination of Three Declarations Authorizing Emergency Use of Medical Devices…](https://policyrisk.com/federal-register/2026-13373)
- [Next: 2026-13376, Initiation of Five-Year (Sunset) Reviews](https://policyrisk.com/federal-register/2026-13376)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-13374 (as of 2026-07-09).
